TPCW
ABBV icon

TD Private Client Wealth’s AbbVie ABBV Stock Holding History

TD Private Client Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.4M Sell
66,201
-1,872
-3% -$415K 0.3% 57
2025
Q4 		$15.6M Sell
68,073
-9,822
-13% -$2.24M 0.33% 50
2025
Q3 		$18M Sell
77,895
-2,251
-3% -$458K 0.41% 46
2025
Q2 		$14.9M Buy
80,146
+1,193
+2% +$222K 0.37% 50
2025
Q1 		$16.5M Buy
78,953
+10,609
+16% +$2.06M 0.46% 41
2024
Q4 		$12.1M Sell
68,344
-2,067
-3% -$380K 0.34% 54
2024
Q3 		$13.9M Sell
70,411
-312
-0.4% -$58.2K 0.4% 45
2024
Q2 		$12.1M Buy
70,723
+5,758
+9% +$954K 0.38% 46
2024
Q1 		$11.8M Sell
64,965
-8,259
-11% -$1.42M 0.39% 49
2023
Q4 		$11.4M Sell
73,224
-2,749
-4% -$401K 0.41% 47
2023
Q3 		$11.3M Buy
75,973
+313
+0.4% +$45.9K 0.49% 37
2023
Q2 		$10.2M Sell
75,660
-16,734
-18% -$2.45M 0.44% 43
2023
Q1 		$14.7M Sell
92,394
-1,410
-2% -$216K 0.66% 28
2022
Q4 		$15.2M Sell
93,804
-3,913
-4% -$600K 0.72% 28
2022
Q3 		$13.1M Sell
97,717
-343
-0.3% -$49.2K 0.67% 27
2022
Q2 		$15M Sell
98,060
-16,557
-14% -$2.53M 0.73% 24
2022
Q1 		$18.6M Sell
114,617
-5,387
-4% -$783K 0.79% 21
2021
Q4 		$16.2M Sell
120,004
-4,147
-3% -$490K 0.67% 23
2021
Q3 		$13.4M Buy
124,151
+4,218
+4% +$482K 0.57% 34
2021
Q2 		$13.5M Buy
119,933
+189
+0.2% +$21.3K 0.58% 31
2021
Q1 		$13M Buy
119,744
+957
+0.8% +$102K 0.61% 28
2020
Q4 		$12.7M Sell
118,787
-2,785
-2% -$268K 0.65% 29
2020
Q3 		$10.6M Sell
121,572
-185
-0.2% -$17.4K 0.6% 31
2020
Q2 		$12M Sell
121,757
-5,554
-4% -$489K 0.7% 29
2020
Q1 		$9.7M Buy
127,311
+4,941
+4% +$421K 0.69% 29
2019
Q4 		$10.8M Buy
+122,370
New +$10.2M 0.65% 34

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TD Private Client Wealth's ABBV Position: Q1 2026 in Review

TD Private Client Wealth reduced its AbbVie (ABBV) stake by 2.7% in Q1 2026, selling an estimated $415K and leaving 66,201 shares worth $14.4M. The position accounts for 0.3% of the portfolio, ranked #57.

TD Private Client Wealth first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $18.6M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • TD Private Client Wealth held 66,201 shares of AbbVie worth $14.4M as of Q1 2026.
  • TD Private Client Wealth sold 1,872 AbbVie shares in Q1 2026, an estimated $415K.
  • AbbVie made up 0.3% of TD Private Client Wealth's portfolio in Q1 2026, its #57 holding.
  • TD Private Client Wealth first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • TD Private Client Wealth's AbbVie position peaked at $18.6M in Q1 2022.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.